CNBX Acquires A Controlling Interest In Cancer Immunotherapy Developer

CNBX Pharmaceuticals Inc. CNBX has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd. The TaGeza research team remains committed to the company, and co-founder professor Benjamin Dekel (MD, PhD) will continue to serve as the company's chief scientist; CNBX chairman, Gabriel Yariv, to assume the position of TaGeza Biopharmaceuticals CEO.

TaGeza is a developer of next generation immunotherapy and cancer-targeted therapies. The company is currently developing novel antibody drug conjugates based on novel monoclonal antibodies, targeting specific types of cancer by way of targeting the subpopulation of highly tumorigenic cancerous cells, known as cancer stem cells or tumor initiating cells. Patients undergoing more conventional therapies such as chemotherapy enjoy a reduction in tumor size but can often relapse and even develop a more aggressive disease, in part due to the residual population of chemotherapy-resistant tumor cells are enriched by cancer stem cells or tumor initiating cells. Therefore, targeting cancer stem cells or tumor initiating cells can help improve patient outcome and reduce relapse caused by their aggressive self-renewal and tumorigenic properties as well as their resistance to more conventional therapies.

About CNBX

CNBX Pharmaceuticals is a U.S. public company and a developer of cancer related cannabinoid-based medicine. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.

Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.

Photo: Benzinga; Sources: courtesy of Matthias Zomer via Pexels, squarefrog via Pixabay

Related News

Cannabics Pharmaceuticals Changes Name To CNBX Pharmaceuticals, Moves Ahead With Cancer Treatment Drug Research

Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer

Cannabis Movers & Shakers: Eden Empire, Cannabics Pharmaceuticals, Nabis

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsPenny StocksMarketsBenjamin DekelGabriel YarivpremiumTaGeza Biopharmaceuticals Ltd.
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Top Cannabis Event In New Jersey

Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!


Loading...